Relatively low-dose infliximab (3 mg/kg ... [114] Golimumab, a new human anti-TNF monoclonal antibody, at 50 and 100 mg doses, also inhibited psoriatic artritic and skin lesion and improved ...
In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...
Switching between infliximab biosimilar SB2 and the reference ... Median C-reactive protein (CRP) levels were 2.0 mg/L (IQR, 1.0-4.1) at baseline and 2.4 mg/L (IQR, 1.1-5.2) at week 48, resulting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback